Search

Retina UK aims not only to progress research along established threads, but to stimulate new thinking, encourage innovative approaches and nurture original ideas.

In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.

• News

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

Making yourself aware of the what you are entitled to, and understanding the diagnosis pathway for inherited sight loss, will put you in a stronger position to seek better support.

The Spring 2023 edition of the Retina UK newsletter, Look Forward, which includes articles about our upcoming events, research updates and more.

• Look Forward
• Audio
• Written

These frequently asked questions should provide a response for most of the queries you might raise.

We provide funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease.

If you are considering employing someone with inherited sight loss, or have an employee recently been diagnosed with the condition, you will need to take steps to ensure that you treat them fairly and that they can work safely and effectively.

• Written

These are some of the most commonly asked questions about genetic testing and counselling.

Hajrah Sarkar is a PhD student whose project is funded by Retina UK.

• Case study - research
• Written